Compare CCS & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCS | HRMY |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2014 | 2020 |
| Metric | CCS | HRMY |
|---|---|---|
| Price | $69.12 | $34.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $64.80 | $44.11 |
| AVG Volume (30 Days) | 334.7K | ★ 756.0K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | ★ 0.84 | 0.55 |
| Revenue | ★ $4,117,816,000.00 | $868,453,000.00 |
| Revenue This Year | N/A | $19.75 |
| Revenue Next Year | $10.84 | $12.88 |
| P/E Ratio | $74.74 | ★ $62.11 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $47.28 | $25.52 |
| 52 Week High | $76.00 | $40.87 |
| Indicator | CCS | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 76.37 | 61.21 |
| Support Level | $55.64 | $25.92 |
| Resistance Level | $70.86 | $35.47 |
| Average True Range (ATR) | 2.58 | 1.05 |
| MACD | 1.06 | -0.01 |
| Stochastic Oscillator | 90.58 | 64.81 |
Century Communities Inc is engaged in the development, design, construction, marketing and sale of single-family attached and detached homes. The company builds and sells homes under its Century Communities and Century Complete brands. Its reportable segments for homebuilding operations are: i) West (California and Washington) ii) Mountain (Arizona, Colorado, Nevada and Utah), iii) Texas, iv) Southeast (Florida, Georgia, North Carolina, South Carolina and Tennessee), v) Century Complete (Alabama, Arizona, Florida, Georgia, Indiana, Kentucky, Michigan, North Carolina, and South Carolina). The company's other reportable segments include: Financial Services and Century Living. The company derives the majority of its revenue from the sale of new homes in the Mountain segment.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.